This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Glikman, P. Articles by Bartholomew, M. Search for Related Content PubMed PubMed Citation Articles by Glikman, P. Articles by Bartholomew, M.

Polyamine Involvement in the Growth of Hormone-responsive and -resistant Human Breast Cancer Cells in Culture¹

Departments of Medicine, Pathology and Behavioral Sciences, The Milton S. Hershey Medical Center, The Pennsylvania State University, Hershey, Pennsylvania 17033

Recent evidence indicates that hormone-responsive but not -resistant human breast cancer cells in culture are sensitive to the antiproliferative effect of the polyamine (PA) biosynthetic inhibitor -difluoromethylornithine (DFMO). The present experiments were designed to investigate the potential differential involvement of the PA pathway in the growth of these different biological subtypes of human breast cancer. Thus, we evaluated the effect of DFMO on proliferation, ornithine decarboxylase (ODC) activity, and PA levels of the hormone-dependent MCF-7 and -independent MDA-MB-231 breast cancer cell lines. When tested at comparable cell density, the two cell lines had similar levels of ODC activity and PA. Administration of DFMO (0.01, 0.1, 1, 4 mM) for 6 days caused a similar dose-dependent inhibition of proliferation (up to approximately 15% of control) associated with suppression of ODC activity to undetectable levels at the highest dose. In both cell lines, putrescine and spermidine levels were maximally suppressed by doses of DFMO > 0.1 mM. Higher doses of DFMO (1 and 4 mM) also suppressed spermine levels to approximately 60% of control. In detailed time-course studies, DFMO administration (0.1 mM) similarly suppressed by 80% the rise in ODC observed in both cell lines following a medium change. At all time points, putrescine and spermidine levels were likewise suppressed to a similar extent. Addition of putrescine (0.1–2.5 mM) to DFMO-treated cells repleted cellular PA levels and restored growth to approximately 80% of control in both cell lines. We conclude that, under these experimental conditions, PA are similarly involved in the growth of the hormone-responsive MCF-7 and -resistant MDA-MB-231 human breast cancer cell lines.

¹ This work is supported by a grant from the National Cancer Institute, P01-CA40011.

² Present address: Division Endocrinologia, Hospital J. M. Ramos Mejia, Uriquiza 609, 1221—Buenos Aires, Argentina.

³ To whom requests for reprints should be addressed, at Division of Endocrinology, The Milton S. Hershey Medical Center, P. O. Box 850, Hershey, PA 17033.

Received 1/25/88. Revised 7/ 6/88. Revised 10/31/88. Accepted 12/14/88.

This article has been cited by other articles:

				F. Wu, D. Grossenbacher, and H. Gehring New transition state-based inhibitor for human ornithine decarboxylase inhibits growth of tumor cells Mol. Cancer Ther., June 1, 2007; 6(6): 1831 - 1839. [Abstract] [Full Text] [PDF]

				X. Hu, S. Washington, M. F. Verderame, and A. Manni Interaction between Polyamines and the Mitogen-Activated Protein Kinase Pathway in the Regulation of Cell Cycle Variables in Breast Cancer Cells Cancer Res., December 1, 2005; 65(23): 11026 - 11033. [Abstract] [Full Text] [PDF]

				C. J. Fabian, B. F. Kimler, D. A. Brady, M. S. Mayo, C. H. J. Chang, J. A. Ferraro, C. M. Zalles, A. L. Stanton, S. Masood, W. E. Grizzle, et al. A Phase II Breast Cancer Chemoprevention Trial of Oral {alpha}-Difluoromethylornithine: Breast Tissue, Imaging, and Serum and Urine Biomarkers Clin. Cancer Res., October 1, 2002; 8(10): 3105 - 3117. [Abstract] [Full Text] [PDF]

				J. A. O'Shaughnessy, L. M. Demers, S. E. Jones, J. Arseneau, P. Khandelwal, T. George, R. Gersh, D. Mauger, and A. Manni {{alpha}}-Difluoromethylornithine as Treatment for Metastatic Breast Cancer Patients Clin. Cancer Res., November 1, 1999; 5(11): 3438 - 3444. [Abstract] [Full Text] [PDF]